Canadian Non-Interventional Prospective Cohort Study on the Real - Life Assessment of Abilify Maintena in Schizophrenia
Phase of Trial: Phase IV
Latest Information Update: 24 May 2017
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms ReLiAM
- Sponsors Lundbeck Canada
- 24 May 2017 Results of an interim analysis at 12-months (n=192), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 09 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017.
- 21 Nov 2016 Status changed from recruiting to discontinued.